CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

8 years ago

CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

On April 28, 2017, Cellular Biomedicine Group, Inc. (the Company)
completed its 2017 annual meeting of stockholders (the “Annual
Meeting”). The number of shares of common stock entitled to vote
at the Annual Meeting was 14,281,350 shares. The number of shares
of common stock present or represented by valid proxy at the
Annual Meeting was 9,384,155 shares. All matters submitted to a
vote of the Company’s stockholders at the Annual Meeting were
approved, and Chun Kwok Alan Au, Gang Ji and Bizuo (Tony) Liu
were elected Class II directors.

The following is a tabulation of the voting on the proposals
presented at the Annual Meeting:

(i) To elect three (3) Class II directors, each of whom will be
elected for a term of three years, or until the election and
qualification of their successors.

Nominee	Shares Voted For	Shares Withheld	Broker Non-Vote
Chun Kwok Alan Au	9,179,543	204,612	0
Gang Ji	9,316,316	67,839	0
Bizuo (Tony) Liu	9,301,819	82,336	0

(ii) To ratify the appointment of BDO China Shu Lun Pan Certified
Public Accountants LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017.

Shares Voted For		Shares Voted Against		Shares Abstaining		Broker Non-Vote
9,316,279		67,666		210		0

(iii) To approve an amendment to the Cellular Biomedicine Group,
Inc. 2014 Stock Incentive Plan to increase the number of shares
available for issuance thereunder by 1,000,000 shares.

Shares Voted For		Shares Voted Against		Shares Abstaining		Broker Non-Vote
8,399,504		982,861		1,790		0

(iv) To conduct a non-binding advisory vote on the Companys
executive compensation.

Shares Voted For		Shares Voted Against		Shares Abstaining		Broker Non-Vote
9,313,915		68,437		1,803		0

Item 7.01Regulation FD Disclosure.

On May 1, 2017, the Company issued a press release announcing the
results of the Annual Meeting. A copy of the press release is
attached hereto as Exhibit 99.1.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

99.1 Press Release, dated May 1, 2017

About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session up +0.20 at 11.00 with 14,358 shares trading hands.